Yale University
To test the hypothesis that estrogen suppression impairs endothelial dysfunction in endometriosis.
Our scientific premise is that in women with endometriosis, elevated cardiovascular disease risk is the result of endothelial dysfunction and chronic systemic inflammation through lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) receptor activation. This cardiovascular disease risk is exacerbated by standard estrogen suppression treatments.
Inclusion Criteria: * Young women between the ages of 18 and 45 years (Controls); * Young women between the ages of 18 and 45 years with endometriosis. Exclusion Criteria: * Subjects who smoke * Subjects who have diabetes, * Subjects with sleep apnea or BP\>140/90 will be excluded. * Women with endometriosis and severe acute pain requiring immediate treatment will be excluded.
Elagolix, 400 mg/day oral, 2X200 mg tablets/day for 4 days.
Verify or correct the compensation shown for this listing.